Immunotherapy of cancer through targeting of the p53 tumor antigen

Archivum Immunologiae et Therapiae Experimentalis

Volumn 50, Issue 5, 2002, Pages 297-305

  Zwaveling, Sander ^a,b   Van der Burg, Sjoerd H ^a   Menon, Anand G ^a   Melief, Cornelis J M ^a   Offringa, Rienk ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Surgery ^*  (Netherlands)

Author keywords

Cancer immunotherapy; P53 tumor antigen

Indexed keywords

PROTEIN P53; TUMOR ANTIGEN; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2;

AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELLULAR IMMUNITY; COLORECTAL CANCER; HELPER CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; ANIMAL; ANTIGEN PRESENTATION; COLORECTAL TUMOR; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; NEOPLASM;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; AUTOIMMUNITY; COLORECTAL NEOPLASMS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; NEOPLASMS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036450278     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Angelopoulou K., Diamandis E. P., Sutherland D. J., Kellen J. A. and Bunting P. S. (1994): Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int. J. Cancer, 58, 480-487.
2. Ashcroft M. and Vousden K. H. (1999): Regulation of p53 stability. Oncogene, 18, 7637-7643.
3. Barfoed A. M., Petersen T. R., Kirkin A. F., Thor Straten P., Claesson M. H. and Zeuthen J. (2000): Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells in vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand. J. Immunol., 51, 128-133.
4. Bennett S. R., Carbone F. R., Karamalis F., Flavell R. A., Miller J. F. and Heath W. R. (1998): Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature, 393, 478-480.
5. Bergstedt-Lindqvist S., Sideras P., MacDonald H. R. and Severinson E. (1984): Regulation of Ig class secretion by soluble products of certain T-cell lines. Immunol. Rev., 78, 25-50.
6. Bristol J. A., Orsini C., Lindinger P., Thalhamer J. and Abrams S. I. (2000): Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization. Cell. Immunol., 205, 73-83.
7. Chikamatsu K., Nakano K., Storkus W. J., Appella E., Lotze M. T., Whiteside T. L. and DeLeo A. B. (1999): Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin. Cancer Res., 5, 1281-1288.
8. Coffman R. L., Seymour B. W., Lebman D. A., Hiraki D. D., Christiansen J. A., Shrader B., Cherwinski H. M., Savelkoul H. F., Finkelman F. D., Bond M. W. and Mosmann T. R. (1988): The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol. Rev., 102, 5-28.
9. Crawford L. V., Pim D. C. and Lamb P. (1984): The cellular protein p53 in human tumours. Mol. Biol. Med., 2, 261-272.
10. DeLeo A. B., Jay G., Appella E., Dubois G. C., Law L. W. and Old L. J. (1979): Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA, 76, 2420-2424.
11. Del Sal G., Murphy M., Ruaro E., Lazarevic D., Levine A. J. and Schneider C. (1996): Cyclin D1 and p21/waf1 are both involved in p53 growth suppression. Oncogene, 12, 177-185.
12. Dutta A., Ruppert J. M., Aster J. C. and Winchester E. (1993): Inhibition of DNA replication factor RPA by p53. Nature, 365, 79-82.
13. Erdile L. F. and Smith D. (2000): CD40 activation enhances the magnitude of cellular immune responses against p53 but not the avidity of the effectors. Cancer Immunol. Immunother., 49, 410-416.
14. Eura M., Chikamatsu K., Katsura F., Obata A., Sobao Y., Takiguchi M., Song Y., Appella E., Whiteside T. L. and DeLeo A. B. (2000): A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. Clin. Cancer Res., 6, 979-986.
15. Fedoseyeva E. V., Boisgerault F., Anosova N. G., Wollish W. S., Arlotta P., Jensen P. E., Ono S. J. and Benichou G. (2000): CD4+ T cell responses to self and mutated p53 determinants during tumorigenesis in mice. J. Immunol., 164, 5641-5651.
16. Fodde R., Smits R. and Clevers H. (2001): APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. Cancer, 1, 55-67.
17. Fujita H., Senju S., Yokomizo H., Saya H., Ogawa M., Matsushita S. and Nishimura Y. (1998): Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. Eur. J. Immunol., 28, 305-316.
18. Gnjatic S., Cai Z., Viguier M., Chouaib S., Guillet J. G. and Choppin J. (1998): Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J. Immunol., 160, 328-333.
19. Greenberg P. D. (1991): Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol., 49, 281-355.
20. Hernandez J., Ko A. and Sherman L. A. (2001): CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen. J. Immunol., 166, 3908-3914.
21. Hernandez J., Lee P. P., Davis M. M. and Sherman L. A. (2000): The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J. Immunol., 164, 596-602.
22. Hiranuma K., Tamaki S., Nishimura Y., Kusuki S., Isogawa M., Kim G., Kaito M., Kuribayashi K., Adachi Y. and Yasutomi Y. (1999): Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus. J. Gen. Virol., 80, 187-193.
23. Hollstein M., Sidransky D., Vogelstein B. and Harris C. C. (1991): p53 mutations in human cancers. Science, 253, 49-53.
24. Honda R., Tanaka H. and Yasuda H. (1997): Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett., 420, 25-27.
25. Houbiers J. G., Nijman H. W., van der Burg S. H., Drijfhout J. W., Kenemans P., Van De Velde C. J., Brand A., Momburg F., Kast W. M. and Melief C. J. (1993): In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol., 23, 2072-2077.
26. Houbiers J. G., van der Burg S. H., Van De Watering L. M., Tollenaar R. A., Brand A., Van De Velde C. J. and Melief C. J. (1995): Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br. J. Cancer, 72, 637-641.
27. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D. and Levitsky h. (1998): The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med., 188, 2357-2368.
28. Hurpin C., Rotarioa C., Bisceglia H., Chevalier M., Tartaglia J. and Erdile L. (1998): The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity. Vaccine, 16, 208-215.
29. Ishida T., Chada S., Stipanov M., Nadaf S., Ciernik F. I., Gabrilovich D. I. and Carbone D. P. (1999): Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin. Exp. Immunol., 117, 244-251.
30. Kast W. M., Offringa R., Peters P. J., Voordouw A. C., Meloen R. H., van der Eb A. J. and Melief C. J. (1989): Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell, 59, 603-614.
31. Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B. and Craig R. W. (1991): Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304-6311.
32. Kessels H. W., Wolkers M. C., Van Den Boom M. D., Van Der Valk M. A. and Schumacher T. N. (2001): Immunotherapy through TCR gene transfer. Nat. Immunol., 2, 957-961.
33. Knutson K. L., Schiffman K. and Disis M. L. (2001): Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest., 107, 477-484.
34. Lane D. P. and Crawford L. V. (1979): T antigen is bound to a host protein in SV40-transformed cells. Nature, 278, 261-263.
35. Levine A. J., Momand J. and Finlay C. A. (1991): The p53 tumour suppressor gene. Nature, 351, 453-456.
36. Mayo L. D., Turchi J. J. and Berberich S. J. (1997): Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res., 57, 5013-5016.
37. Mayordomo J. I., Loftus D. J., Sakamoto H., De Cesare C. M., Appasamy P. M., Lotze M. T., Storkus W. J., Appella E. and DeLeo A. B. (1996): Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med., 183, 1357-1365.
38. Melief C. J., Toes R. E., Medema J. P., van der Burg S. H., Ossendorp F. and Offringa R. (2000): Strategies for immunotherapy of cancer. Adv. Immunol., 75, 235-282.
39. Momand J., Zambetti G. P., Olson D. C., George D. and Levine A. J. (1992): The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237-1245.
40. Nijman H. W., van der Burg S. H., Vierboom M. P., Houbiers J. G., Kast W. M. and Melief C. J. (1994): p53, a potential target for tumor-directed T cells. Immunol. Lett., 40, 171-178.
41. Offringa R., Vierboom M. P., van der Burg S. H., Erdile L. and Melief C. J. (2000): p53: a potential target antigen for immunotherapy of cancer. Ann. NY Acad. Sci., 910, 223-233; discussion 233-226.
42. Ossendorp F., Mengede E., Camps M., Filius R. and Melief C. J. (1998): Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med., 187, 693-702.
43. Partidos C. D., Vohra P. and Steward M. W. (1996): Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides. Immunology, 87, 179-185.
44. Ras E., van der Burg S. H., Zegveld S. T., Brandt R. M., Kuppen P. J., Offringa R., Warnarr S. O., Van De Velde C. J. and Melief C. J. (1997): Identification of potential HLA-A*0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). Hum. Immunol., 53, 81-89.
45. Reich N. C., Oren M. and Levine A. J. (1983): Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol. Cell. Biol., 3, 2143-2150.
46. Ridge J. P., Di Rosa F. and Matzinger P. (1998): A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature, 393, 474-478.
47. Rogel A., Popliker M., Webb C. G. and Oren M. (1985): p53 cellular tumor antigen: Analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol. Cell. Biol., 5, 2851-2855.
48. Romerdahl C. A. and Kripke M. L. (1988): Role of helper T-lymphocytes in rejection of UV-induced murine skin cancers. Cancer Res., 48, 2325-2328.
49. Ropke M., Hald J., Guldberg P., Zeuthen J., Norgaard L., Fugger L., Svejgaard A., van der Burg S., Nijman H. W., Melief C. J. and Claesson M. H. (1996): Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl. Acad. Sci. USA, 93, 14704-14707.
50. Rosenwirth B., Kuhn E. M., Heeney J. L., Hurpin C., Tartaglia J., Bonnet M. C., Moingeon P. and Erdile L. (2001): Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the intravenous route in rhesus macaques. Vaccine, 19, 1661-1670.
51. Roth J., Dittmer D., Rea D., Tartaglia J., Paoletti E. and Levine A. J. (1996): p53 as a target for cancer vaccines: Recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc. Natl. Acad. Sci. USA, 93, 4781-4786.
52. Sadovnikova E., Jopling L. A., Soo K. S. and Stauss H. J. (1998): Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur. J. Immunol., 28, 193-200.
53. Sadovnikova E. and Stauss H. J. (1996): Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: Reagents for tumor immunotherapy. Proc. Natl. Acad. Sci. USA, 93, 13114-13118.
54. Saeterdal I., Bjorheim J., Lislerud K., Gjertsen M. K., Bukholm I. K., Olsen O. C., Nesland J. M., Eriksen J. A., Moller M., Lindblom A. and Gaudernack G. (2001): Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc. Natl. Acad. Sci. USA, 98, 13255-13260.
55. Schild H. J., Kyewski B., Von Hoegen P. and Schirrmacher V. (1987): CD4+ helper T cells are required for resistance to a highly metastatic murine tumor. Eur. J. Immunol., 17, 1863-1866.
56. Schoenberger S. P., Toes R. E., van der Voort E. I., Offringa R. and Melief C. J. (1998): T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature, 393, 480-483.
57. Shieh S. Y., Ikeda M., Taya Y. and Prives C. (1997): DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell, 91, 325-334.
58. Shirai M., Pendleton C. D., Ahlers J., Takeshita T., Newman M. and Berzofsky J. A. (1994): Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J. Immunol., 152, 549-556.
59. Stanislawski T., Voss R. H., Lotz C., Sadovnikova E., Willemsen R. A., Kuball J., Ruppert T., Bolhuis R. L., Melief C. J., Huber C., Stauss H. J. and Theobald M. (2001): Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol., 2, 962-970.
60. Stauss H. J. (1999): Immunotherapy with CTLs restricted by nonself MHC. Immunol. Today, 20, 180-183.
61. Theobald M., Biggs J., Dittmer D., Levine A. J. and Sherman L. A. (1995): Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA, 92, 11993-11997.
62. Theobald M., Biggs J., Hernandez J., Lustgarten J., Labadie C. and Sherman L. A. (1997): Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med., 185, 833-841.
63. Tilkin A. F., Lubin R., Soussi T., Lazar V., Janin N., Mathieu M. C., Lefrere I., Carlu C., Roy M., Kayibanda M., Bellet D., Guillet J. G. and Paillerets B. B. (1995): Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur. J. Immunol., 25, 1765-1769.
64. Toes R. E., Ossendorp F., Offringa R. and Melief C. J. (1999): CD4 T cells and their role in antitumor immune responses. J. Exp. Med., 189, 753-756.
65. Tuting T., Deleo A. B., Lotze M. T. and Storkus W. J. (1997): Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur. J. Immunol., 27, 2702-2707.
66. Tuting T., Gambotto A., Robbins P. D., Storkus W. J. and Deleo A. B. (1999): Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: Studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Ther., 6, 629-636.
67. Van Den Eynde B. J. and Morel S. (2001): Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. Curr. Opin. Immunol., 13, 147-153.
68. van der Burg S. H., De Cock K., Menon A. G., Franken K. L., Palmen M., Redeker A., Drijfhout J., Kuppen P. J., Van De Velde C., Erdile L., Tollenaar R. A., Melief C. J. and Offringa R. (2001): Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. Eur. J. Immunol., 31, 146-155.
69. van der Burg S. H., Menon A. G., Redeker A., Bonnet M. C., Drijfhout J. W., Tollenaar R. A., Van De Velde C. J., Moingeon P., Kuppen P. J., Offringa R. and Melief C. J. (2002): Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin. Cancer Res., 8, 1019-1027.
70. Vierboom M. P., Nijman H. W., Offringa R., van der Voort E. I., Van Hall T., Van Den Broek l., Fleuren G. J., Kenemans P., Kast W. M. and Melief C. J. (1997): Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med., 186, 695-704.
71. Wang X. W., Yeh H., Schaeffer L., Roy R., Moncollin V., Egly J. M., Wang Z., Freidberg E. C., Evans M. K., Taffe B. G. et al. (1995): p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat. Genet., 10, 188-195.
72. Wiedenfeld E. A., Fernandez-Vina M., Berzofsky J. A. and Carbone D. P. (1994): Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA-A*0201 peptide consensus motif. Cancer Res., 54, 1175-1177.
73. Woerner S. M., Gebert J., Yuan Y. P., Sutter C., Ridder R., Bork P. and Von Knebel Doeberitz M. (2001): Systematic identification of genes with coding microsatellites mutated in DNA mismatch repair-deficient cancer cells. Int. J. Cancer, 93, 12-19.
74. Zambetti G. P. and Levine A. J. (1993): A comparison of the biological activities of wild-type and mutant p53. FASEB J., 7, 855-865.
75. Zwaveling S., Ferreira Mota S. C., Nouta J., Johnson M., Lipford G. B., Offringa R., van der Burg S. H., and Melief C. J. (2002): Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol., 169, 350-358.